FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to paediatrics, and can be used for correction of disturbed neuropsychic state of children with reactive asthenic syndrome. Method involves using a combination of preparations of carnitine and coenzyme Q10 while taking the vitamin-mineral complex Complivit Active depending on the form of asthenic syndrome and the child’s weight. In children with hypersthenic asthenia, therapy with these preparations is started with minimum age doses of carnitine 25–30 mg/kg/day for a month, thereafter, the doses are increased to average therapeutic doses, namely: 45–50 mg/kg/day; preparations of coenzyme Q10 — kudesan are started with average therapeutic 3 mg/kg/day for a month, after that, doses are reduced to preventive ones, namely: 1.5–2 mg/kg/day. In children with hyposthenic asthenia, therapy with these preparations is started with high age doses of carnitine: 75–100 mg/kg/day for a month, after that, switching to the use of medium therapeutic, namely: 45–50 mg/kg/day; preparations of coenzyme Q10 — kudesan are started with average therapeutic doses — 3 mg/kg/day for a month, after which the doses are reduced to preventive ones, namely: 1.5–2 mg/kg/day. Above preparations are used with the vitamin-mineral complex Complivit Active as per table 1 time/day after meals with sufficient amount of liquid. Therapeutic course is performed for 6 months.
EFFECT: use of the invention enables to achieve optimization of mnestic functions and intelligence of a child, especially during mental stress, and also provides support for the nervous system during the period of stress by activating metabolic processes in the cells of brain tissues and its vegetative centres, enhancing the energy supply of the body, which causes increased efficiency and body resistance to physical, intellectual and emotional stress, reduced fatigue, as well as increased body adaptation reactions.
1 cl, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING AND PREVENTING COGNITIVE DISORDERS ASSOCIATED WITH EXPOSURE TO PRODUCTION-INDUCED MANGANESE FROM EXTERNAL ENVIRONMENT IN CHILDREN AGED 5 THROUGH 10 YEARS OLD | 2014 |
|
RU2546523C1 |
METHOD FOR CORRECTING COGNITIVE DISORDERS IN PATIENTS WITH ARTERIAL HYPERTENSION ACCOMPANYING TYPE 2 DIABETES MELLITUS | 2014 |
|
RU2555334C1 |
METHOD FOR CORRECTING INCREASED LEVELS OF ANXIETY AND DEPRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION ACCOMPANYING TYPE 2 DIABETES MELLITUS | 2014 |
|
RU2554806C1 |
METHOD FOR CORRECTION OF LIPOPEROXIDATION ACCOMPANYING HYPOLIPIDEMIC THERAPY OF PATIENTS WITH METABOLIC SYNDROME | 2011 |
|
RU2458687C1 |
METHOD FOR COMPLEX TREATMENT OF METABOLIC SYNDROME | 2015 |
|
RU2616125C1 |
METHOD OF TREATING METABOLIC SYNDROME | 2015 |
|
RU2583944C1 |
METHOD OF TREATING CONGENITAL STRUCTURAL MYOPATHIES AND CONGENITAL MUSCULAR DYSTROPHIES BY CORRECTION OF SECONDARY MITOCHONDRIAL CHANGES | 2008 |
|
RU2400221C2 |
METHOD FOR TREATING COGNITIVE DISORDERS IN CHILDREN WITH TUBEROUS SCLEROSIS DUE TO CORRECTING MITOCHONDRIAL DYSFUNCTION | 2004 |
|
RU2271201C2 |
PHARMACEUTICAL NEUROPROTECTIVE, ANTIOXIDANT, ANTIHYPOXIC, ANTIAPOPTOTIC AND MEMBRANE PROTECTIVE COMPOSITION AND METHOD OF TREATMENT | 2008 |
|
RU2385722C1 |
DIAGNOSTIC TECHNIQUE FOR ASTHENIC SYNDROME IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2709105C1 |
Authors
Dates
2024-03-25—Published
2023-05-03—Filed